• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying

    5/22/24 9:09:28 AM ET
    $ACDC
    $ASTC
    $GL
    $IMNM
    Oilfield Services/Equipment
    Energy
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ACDC alert in real time by email

    Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform.

    ProFrac Holding

    • The Trade: ProFrac Holding Corp. (NASDAQ:ACDC) 10% owner Dan H. Wilks acquired a total of 1,013,930 shares at an average price of $13.15. To acquire these shares, it cost around $13.34 million. The company's Executive Chairman Matthew Wilks also bought 10,000 shares.
    • What's Happening: ProFrac Holding said Lance Turner will resign as CFO effective June 17.
    • What ProFrac Holding Does: ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources.

    Immunome

    • The Trade: Immunome, Inc. (NASDAQ:IMNM) President and CEO Clay B Siegall acquired a total of 100,000 shares at an average price of $13.88. To acquire these shares, it cost around $1.39 million.
    • What's Happening: On May 14, Immunome posted downbeat quarterly results.
    • What Immunome Does: Immunome Inc is a biopharmaceutical company.

    Don’t forget to check out our premarket coverage here

    Globe Life

    • The Trade: Globe Life Inc. (NYSE:GL) Co-Chairman and CEO Frank M Svoboda bought a total of 2,500 shares at an average price of $86.31. To acquire these shares, it cost around $215,764.
    • What's Happening: On May 21, Raymond James analyst Wilma Burdis reiterated Globe Life with a Strong Buy.
    • What Globe Life Does: Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers.

    Astrotech

    • The Trade: Astrotech Corporation (NASDAQ:ASTC) Director Thomas Wiley Wilkinson bought a total of 1,109 shares at an average price of $9.50. The insider spent around $10,536 to buy those shares.
    • What's Happening: On May 13, Astrotech posted a wider loss for the third quarter.
    • What Astrotech Does: Astrotech Corp is a science and technology development company.

    Check This Out: Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month

    Get the next $ACDC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACDC
    $ASTC
    $GL
    $IMNM

    CompanyDatePrice TargetRatingAnalyst
    Immunome Inc.
    $IMNM
    2/12/2026$40.00Buy
    H.C. Wainwright
    Globe Life Inc.
    $GL
    1/6/2026$155.00Outperform → In-line
    Evercore ISI
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    Immunome Inc.
    $IMNM
    9/22/2025$26.00Buy
    Goldman
    Immunome Inc.
    $IMNM
    9/5/2025$26.00Buy
    Craig Hallum
    Globe Life Inc.
    $GL
    8/5/2025$166.00Equal-Weight → Overweight
    Morgan Stanley
    ProFrac Holding Corp.
    $ACDC
    7/15/2025$8.00Neutral
    Piper Sandler
    Globe Life Inc.
    $GL
    7/15/2025$150.00Buy
    Truist
    More analyst ratings

    $ACDC
    $ASTC
    $GL
    $IMNM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Globe Life Inc.

    SCHEDULE 13G/A - GLOBE LIFE INC. (0000320335) (Subject)

    3/26/26 6:35:42 PM ET
    $GL
    Life Insurance
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.

    SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)

    3/26/26 11:43:12 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Immunome Inc.

    144 - Immunome Inc. (0001472012) (Subject)

    3/20/26 12:56:11 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACDC
    $ASTC
    $GL
    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Immunome with a new price target

    H.C. Wainwright initiated coverage of Immunome with a rating of Buy and set a new price target of $40.00

    2/12/26 7:24:43 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Globe Life downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Globe Life from Outperform to In-line and set a new price target of $155.00

    1/6/26 8:39:27 AM ET
    $GL
    Life Insurance
    Finance

    Truist initiated coverage on Immunome with a new price target

    Truist initiated coverage of Immunome with a rating of Buy and set a new price target of $36.00

    12/1/25 8:29:07 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACDC
    $ASTC
    $GL
    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 188,500 shares of common stock to thirteen new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal

    4/2/26 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProFrac and Seismos Deploy Closed-Loop Fracturing at Commercial Scale Using Direct In-Well Measurements

    WILLOW PARK, Texas and AUSTIN, Texas, March 12, 2026 /PRNewswire/ -- ProFrac Holding Corp. (NASDAQ:ACDC) ("ProFrac"), in partnership with Seismos, Inc. ("Seismos"), announced today the successful completion of their fully closed-loop fracturing program, demonstrating the first real-time, intra-stage optimization utilizing in-well subsurface measurements and immediate surface actuation. The program took place in the Eagle Ford & Austin Chalk basins with a 4-well pad configuration. From February 13 to March 4, 2026, 183 stages were completed utilizing the ProFrac-Seismos leading-edge, closed-loop fracturing technology.

    3/12/26 7:30:00 AM ET
    $ACDC
    Oilfield Services/Equipment
    Energy

    ProFrac Holding Corp. Reports Full Year and Fourth Quarter 2025 Results

    ProFrac Holding Corp. (NASDAQ:ACDC) ("ProFrac", or the "Company") today announced financial and operational results for its 2025 full year and fourth quarter ended December 31, 2025. Full Year 2025 Results Total revenue was $1.94 billion compared to revenue of $2.19 billion in 2024 Net loss was $356 million compared to net loss of $208 million in 2024 Adjusted EBITDA¹ was $310 million compared to $501 million in 2024; 16% of revenue in 2025 compared to 23% of revenue in 2024 Net cash provided by operating activities was $190 million compared to $367 million in 2024 Capital expenditures totaled $170 million compared to $255 million in 2024 Free cash flow² was $25 million

    3/12/26 5:15:00 AM ET
    $ACDC
    Oilfield Services/Equipment
    Energy

    $ACDC
    $ASTC
    $GL
    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bienaime Jean Jacques bought $43,670 worth of shares (2,000 units at $21.84), increasing direct ownership by 5% to 38,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    3/12/26 6:05:05 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Blinn Mark A bought $153,540 worth of shares (2,000 units at $76.77) (SEC Form 4)

    4/A - GLOBE LIFE INC. (0000320335) (Issuer)

    2/10/26 7:09:12 PM ET
    $GL
    Life Insurance
    Finance

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACDC
    $ASTC
    $GL
    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Higgins Jack

    4 - Immunome Inc. (0001472012) (Issuer)

    4/3/26 7:48:14 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rosett Max

    4 - Immunome Inc. (0001472012) (Issuer)

    4/3/26 7:46:52 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wilks Johnathan Ladd

    4 - ProFrac Holding Corp. (0001881487) (Issuer)

    4/1/26 5:51:59 PM ET
    $ACDC
    Oilfield Services/Equipment
    Energy

    $ACDC
    $ASTC
    $GL
    $IMNM
    Leadership Updates

    Live Leadership Updates

    View All

    GLOBE LIFE INC. DECLARES DIVIDEND AND ANNOUNCES APPOINTMENT OF TWO NEW BOARD MEMBERS

    MCKINNEY, Texas, Feb. 26, 2026 /PRNewswire/ -- Globe Life Inc. (NYSE:GL) announced that its Board of Directors has raised the quarterly dividend to $0.3300 per share on all of the outstanding common stock of the Company held of record as of close of business of the Company's transfer agent on April 3, 2026. The dividend will be paid on May 1, 2026. Globe Life Inc. also announced today that Derek T. Kan, Vice President of Business Operations, Shopify, Inc., and Sandra L. Phillips, Senior Vice President Enterprise Integrity, Chief Legal Officer, Corporate Secretary and Chief Susta

    2/26/26 4:46:00 PM ET
    $GL
    $MSA
    $TOL
    Life Insurance
    Finance
    Industrial Specialties
    Health Care

    Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

    AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025. Financial Highlights & Recent Developments Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system in approximately 35 locations in 16 countries across the United States, Europe and As

    2/13/26 8:15:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™

    AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") today announced that its subsidiary, 1st Detect Corporation ("1st Detect"), has appointed industry veteran, David Spada, as Director of Global Sales. This strategic hire strengthens 1st Detect's commercial leadership as the company scales deployment of its TRACER 1000™ mass spectrometry-based explosives and narcotics trace detector across international security markets. Mr. Spada brings over a decade of specialized trace detection experience to the 1st Detect team. Throughout his career at Implant Sciences, Morpho Detection, and Rapiscan Systems, Mr. Spada has held position

    1/21/26 4:15:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ACDC
    $ASTC
    $GL
    $IMNM
    Financials

    Live finance-specific insights

    View All

    ProFrac Holding Corp. Reports Full Year and Fourth Quarter 2025 Results

    ProFrac Holding Corp. (NASDAQ:ACDC) ("ProFrac", or the "Company") today announced financial and operational results for its 2025 full year and fourth quarter ended December 31, 2025. Full Year 2025 Results Total revenue was $1.94 billion compared to revenue of $2.19 billion in 2024 Net loss was $356 million compared to net loss of $208 million in 2024 Adjusted EBITDA¹ was $310 million compared to $501 million in 2024; 16% of revenue in 2025 compared to 23% of revenue in 2024 Net cash provided by operating activities was $190 million compared to $367 million in 2024 Capital expenditures totaled $170 million compared to $255 million in 2024 Free cash flow² was $25 million

    3/12/26 5:15:00 AM ET
    $ACDC
    Oilfield Services/Equipment
    Energy

    ProFrac Holding Corp. Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call Schedule

    ProFrac Holding Corp. (NASDAQ:ACDC) ("ProFrac" or the "Company") announced today that it will report its fourth quarter and full year 2025 financial results prior to the Company's conference call, which will be webcasted on Thursday, March 12, 2026, at 11:00 a.m. Eastern / 10:00 a.m. Central. To register for and access the event, please click here. An archive of the webcast will be available shortly after the call's conclusion on the IR Calendar section of ProFrac's investor relations website for 90 days. About ProFrac Holding Corp. ProFrac Holding Corp. is a technology-focused, vertically integrated and innovation-driven energy services holding company providing hydraulic fracturing,

    3/2/26 7:00:00 AM ET
    $ACDC
    Oilfield Services/Equipment
    Energy

    GLOBE LIFE INC. REPORTS FOURTH QUARTER 2025 RESULTS

    MCKINNEY, Texas, Feb. 4, 2026 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) reported today that for the quarter ended December 31, 2025, net income was $3.29 per diluted common share, compared with $3.01 per diluted common share for the year-ago quarter. Net operating income for the quarter was $3.39 per diluted common share, compared with $3.14 per diluted common share for the year-ago quarter. Net income for the year ended December 31, 2025 was $14.07 per diluted common share, compared with $11.94 per diluted common share for the year-ago period. Net operating income for the ye

    2/4/26 4:10:00 PM ET
    $GL
    Life Insurance
    Finance

    $ACDC
    $ASTC
    $GL
    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immunome Inc.

    SC 13G - Immunome Inc. (0001472012) (Subject)

    11/14/24 1:28:33 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Immunome Inc.

    SC 13G - Immunome Inc. (0001472012) (Subject)

    11/14/24 10:33:51 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care